BioLineRx (BLRX) announced the initiation of a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and other high-grade glioma. The Phase 1 part of the trial is expected to recruit up to 30 patients with recurrent and progressive GBM and other high-grade glioma. The objective is to establish a maximum tolerated dose and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial are anticipated in H1 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLRX:
- Options Volatility and Implied Earnings Moves Today, March 23, 2026
- Options Volatility and Implied Earnings Moves This Week, March 23 – March 27, 2026
- BioLineRx Sets March Start for GLIX1 Brain Cancer Trial as 2025 Results Show Leaner R&D-Focused Model
- BioLineRx provides corporate update
- Bioline RX Ltd Sponsored ADR (BLRX) Q4 Earnings Cheat Sheet